122 related articles for article (PubMed ID: 38169056)
1. Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy.
Starchenka S; Oluwayi K; Heath M; Armfield O; Shamji M; Layhadi J; Lis K; Cadavez L; Rusyn O; Skinner M; De Kam PJ
Clin Exp Allergy; 2024 Feb; 54(2):130-142. PubMed ID: 38169056
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy.
Starchenka S; Heath MD; Lineberry A; Higenbottam T; Skinner MA
World Allergy Organ J; 2019 Nov; 12(11):100087. PubMed ID: 31768216
[TBL] [Abstract][Full Text] [Related]
3. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
4. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
[TBL] [Abstract][Full Text] [Related]
6. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
7. Single-cell RNA sequencing identifies precise tolerogenic cellular and molecular pathways induced by depigmented-polymerized grass pollen allergen extract.
Layhadi JA; Moya R; Tan TJ; Lenormand MM; Sharif H; Parkin RV; Vila-Nadal G; Fedina O; Zhu R; Laisuan W; Durham SR; Carnés J; Shamji MH
J Allergy Clin Immunol; 2023 May; 151(5):1357-1370.e9. PubMed ID: 36649758
[TBL] [Abstract][Full Text] [Related]
8. Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.
Zielen S; Kuna P; Aberer W; Lassmann S; Pfaar O; Klimek L; Wade A; Kluehr K; Raab J; Wessiepe D; Lee D; Kramer MF; Gunawardena K; Higenbottam T; Heath MD; Skinner MA; de Kam PJ
World Allergy Organ J; 2019 Nov; 12(11):100075. PubMed ID: 31709029
[TBL] [Abstract][Full Text] [Related]
9. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
10. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.
Wachholz PA; Nouri-Aria KT; Wilson DR; Walker SM; Verhoef A; Till SJ; Durham SR
Immunology; 2002 Jan; 105(1):56-62. PubMed ID: 11849315
[TBL] [Abstract][Full Text] [Related]
11. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
[TBL] [Abstract][Full Text] [Related]
12. Reactivity of T cells with grass pollen allergen extract and allergoid.
Kahler H; Stüwe H; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 1999 Oct; 120(2):146-57. PubMed ID: 10545769
[TBL] [Abstract][Full Text] [Related]
13. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
14. Trichuris suis ova therapy for allergic rhinitis does not affect allergen-specific cytokine responses despite a parasite-specific cytokine response.
Bourke CD; Mutapi F; Nausch N; Photiou DM; Poulsen LK; Kristensen B; Arnved J; Rønborg S; Roepstorff A; Thamsborg S; Kapel C; Melbye M; Bager P
Clin Exp Allergy; 2012 Nov; 42(11):1582-95. PubMed ID: 23106658
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract.
Bousquet J; Hejjaoui A; Skassa-Brociek W; Guérin B; Maasch HJ; Dhivert H; Michel FB
J Allergy Clin Immunol; 1987 Oct; 80(4):591-8. PubMed ID: 3668124
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
17. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
[TBL] [Abstract][Full Text] [Related]
18. Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy.
Altman MC; Segnitz RM; Larson D; Jayavelu ND; Smith MT; Patel S; Scadding GW; Qin T; Sanda S; Steveling E; Eifan AO; Penagos M; Jacobson MR; Parkin RV; Shamji MH; Togias A; Durham SR
J Allergy Clin Immunol; 2023 Nov; 152(5):1247-1260. PubMed ID: 37460024
[TBL] [Abstract][Full Text] [Related]
19. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.
de Kam PJ; Zielen S; Bernstein JA; Berger U; Berger M; Cuevas M; Cypcar D; Fuhr-Horst A; Greisner WA; Jandl M; Laßmann S; Worm M; Matz J; Sher E; Smith C; Steven GC; Mösges R; Shamji MH; DuBuske L; Borghese F; Oluwayi K; Zwingers T; Seybold M; Armfield O; Heath MD; Hewings SJ; Kramer MF; Skinner MA
Allergy; 2023 Oct; 78(10):2756-2766. PubMed ID: 37366581
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study.
Florido-López JF; Andreu-Balaguer C; Escudero C; Seoane-Rodríguez M; Hernández M; Navarro-Seisdedos LÁ; Torrecillas-Toro M; Anton-Girones M; Herrero-Lifona L; Brugaletta D; Macías J; Pineda R; Lara MÁ; López-Caballero J; Rojas MJ
World Allergy Organ J; 2020 Dec; 13(12):100487. PubMed ID: 33376572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
